Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (248)
  3. Review (13)
  4. Guidelines (11)
  5. Research Letter (9)
  6. Book Section (6)
  7. Correspondence (5)
  8. Editorial (4)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (671)
  2. Department of Medicine (671)
  3. Hematologic Malignancies, Division of (671)
  4. Lymphoma (671)
  5. Population Sciences Research Program (671)
  6. Survivorship Research (173)

More Groups

People
  1. Alison Moskowitz (235)
  2. Andrew Zelenetz (169)
  3. Paul Hamlin (140)
  4. Ariela Noy (139)
  5. David Straus (122)
  6. Maria Palomba (112)

More People

Years
  1. 2025 (18)
  2. 2024 (51)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Blood Advances (19)
  5. Leukemia and Lymphoma (19)
  6. Annals of Oncology (18)

More Publications

Publishers
  1. American Society of Hematology (277)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (34)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (23)

More Publishers

Results (671)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center
    Journal Article

    Dashevsky, B. Z.; Gallagher, K. M.; Grabenstetter, A.; Cordeiro, P. G.; Dogan, A.; Morris, E. A.; Horwitz, S. M.; Sutton, E. J.
    Breast Journal (2019)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial
    Journal Article

    Horwitz, S.; O'Connor, O. A.; Pro, B.; Illidge, T.; Fanale, M.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Angioimmunoblastic T-cell lymphoma
    Journal Article

    Yabe, M.; Dogan, A.; Horwitz, S. M.; Moskowitz, A. J.
    Cancer Treatment and Research (2019)

    Fulltext@MSK | Save
  • The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL)
    Meeting Abstract

    Horwitz, S. M.; Soto, J.; Youssoufian, H.; Lloyd, D.; Le, N. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral T cell lymphoma (PTCL)
    Meeting Abstract

    Horwitz, S. M.; Hamlin, P. A.; Feldman, T.; Hess, B. T.; Mato, A. R.; Munoz, J.; Patel, M. R.; Ye, J. C.; Steele, A.; Pandey, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Superior clinical benefit of brentuximab vedotin in mycosis fungoides versus physician's choice irrespective of CD30 level or large cell transformation status in the phase 3 ALCANZA study
    Meeting Abstract

    Kim, Y. H.; Prince, H. M.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Bechter, O.; Sanches, J. A.; Stadler, R.; Scarisbrick, J.; Quaglino, P.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Hamadani, M.; Collins, G. P.; Samaniego, F.; Spira, A. I.; Davies, A.; Radford, J.; Caimi, P.; Menne, T.; Boni, J.; Cruz, H.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: Results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas
    Meeting Abstract

    Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Fanale, M. A.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; more...
    Blood (2018)

    Fulltext@MSK | Save